# | Title | Journal | Year | Citations |
---|
1 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
2 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Proceedings of the National Academy of Sciences of the United States of America | 2007 | 1,557 |
3 | B cells are associated with survival and immunotherapy response in sarcoma | Nature | 2020 | 1,158 |
4 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 767 |
5 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
6 | Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis | Journal of Thoracic Oncology | 2017 | 653 |
7 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2015 | 574 |
8 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 568 |
9 | Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies | Journal of Hepatology | 2017 | 465 |
10 | Management of gastric cancer in Asia: resource-stratified guidelines | Lancet Oncology, The | 2013 | 418 |
11 | Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis | BMJ: British Medical Journal | 2018 | 362 |
12 | The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells | Cancer Cell | 2006 | 308 |
13 | CLINICAL STUDIES WITH CURCUMIN | | 2007 | 308 |
14 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Lancet Oncology, The | 2020 | 300 |
15 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial | Hepatology | 2008 | 277 |
16 | SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy | Journal of Clinical Oncology | 2008 | 249 |
17 | Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study | Hepatology | 2014 | 235 |
18 | Overview of current systemic management of EGFR-mutant NSCLC | Annals of Oncology | 2018 | 229 |
19 | Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study | Molecular Pharmacology | 2002 | 228 |
20 | The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients | Oncotarget | 2016 | 209 |
21 | Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer | Annals of Oncology | 2009 | 206 |
22 | 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial | Journal of Thoracic Oncology | 2016 | 196 |
23 | Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival | Journal of the National Cancer Institute | 2017 | 196 |
24 | CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials | Annals of Oncology | 2018 | 193 |
25 | 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer | Journal of Thoracic Oncology | 2019 | 187 |
26 | Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? | Clinical Cancer Research | 1999 | 186 |
27 | Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma | Cancer | 2004 | 185 |
28 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Nature Medicine | 2022 | 185 |
29 | IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer | Cancer Research | 2011 | 184 |
30 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases | Journal of Thoracic Oncology | 2020 | 178 |
31 | Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells | Autophagy | 2014 | 161 |
32 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | British Journal of Cancer | 2013 | 160 |
33 | Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | Cancer | 2010 | 154 |
34 | Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report | Journal of Thoracic Oncology | 2019 | 152 |
35 | Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer | International Journal of Cancer | 2006 | 151 |
36 | A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer | British Journal of Cancer | 2013 | 146 |
37 | IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) | Annals of Oncology | 2019 | 146 |
38 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis | Journal of Thoracic Oncology | 2015 | 145 |
39 | Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response | Clinical Cancer Research | 2008 | 140 |
40 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Annals of Oncology | 2020 | 138 |
41 | Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2021 | 136 |
42 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | British Journal of Cancer | 2010 | 127 |
43 | The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis | Molecular Cancer | 2014 | 127 |
44 | The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer | Cancer Research | 2017 | 127 |
45 | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study | The Lancet Gastroenterology and Hepatology | 2018 | 127 |
46 | Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer | BMC Cancer | 2019 | 126 |
47 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | Journal of Hepatology | 2010 | 124 |
48 | Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer | Journal of Thoracic Oncology | 2017 | 122 |
49 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | Lancet Respiratory Medicine,the | 2018 | 121 |
50 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Journal of Thoracic Oncology | 2020 | 119 |